SCHEMBL19780195

SCHEMBL19780195

CCc1nccc(OC)c1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
GAA P10253 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
IKBKB O14920 1/20 0.39
NOS3 P29474 3/20 0.37
NOS2 P35228 3/20 0.37
NOS1 P29475 2/20 0.37
KDM4E B2RXH2 3/20 0.37
PDE10A Q9Y233 3/20 0.36
MAPK1 P28482 3/20 0.36
USP2 O75604 2/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
CYP3A4 P08684 2/20 0.36
PDE3B Q13370 2/20 0.36
PDE3A Q14432 2/20 0.36
HIF1A Q16665 2/20 0.36
RAB9A P51151 2/20 0.36
PDE2A O00408 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12819972 0.78 MAPT (0.39) MAPTSMN1; SMN2GAATDP1KDM4E
SCHEMBL11918960 0.78 RAB9A (0.42) MAPTSMN1; SMN2KDM4EPDE10AMAPK1
SCHEMBL16921629 0.77 ALOX5 (0.41) MAPTSMN1; SMN2GAATDP1KDM4E
SCHEMBL19629675 0.77 HASPIN (0.37) MAPTSMN1; SMN2GAATDP1KDM4E
SCHEMBL12945995 0.77 CYP3A4 (0.34) MAPTSMN1; SMN2KDM4EPDE10AMAPK1
SCHEMBL2954177 0.75 NOS3 (0.52) MAPTGAATDP1IKBKBNOS3
SCHEMBL29745025 0.75 NOS3 (0.52) MAPTGAATDP1IKBKBNOS3
SCHEMBL3064440 0.75 NOS2 (0.42) MAPTSMN1; SMN2GAATDP1NOS3
SCHEMBL31214470 0.74 PDE10A (0.38) MAPTSMN1; SMN2GAATDP1KDM4E
SCHEMBL31214455 0.74 SMN1; SMN2 (0.35) MAPTSMN1; SMN2GAATDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 MAPT 3109/4885SMN1; SMN2 1197/4885GAA 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.